

TABLE OF CONTENTS

1	INTRODUCTION	1
1.1	Types of lung cancer.....	1
1.1.1	Small cell lung cancer (SCLC)	1
1.1.2	Non-small cell lung cancer (NSCLC)	1
1.2	Key statistics	2
1.3	Lung cancer staging.....	3
1.4	Drug Resistance in Cancer	3
1.5	Docetaxel	4
1.6	RNAi MECHANISM	5
1.7	Combinatorial approach.....	7
1.8	Targeted therapy.....	7
1.9	Role of nanocarriers and gene delivery	7
1.9.1	PLHNCs (Polymeric Lipid Hybrid Nanocarriers)	9
1.10	DRY POWDER INHALER TECHNOLOGY	9
1.11	Objective of work.....	9
1.12	rationale.....	10
1.13	hypothesis.....	10
1.14	expected outcomes.....	11
1.15	work plan.....	11
1.16	References	13
2	LITERATURE REVIEW	16
2.1	Lung Cancer	16
2.1.1	Risk factors for lung cancer.....	16
2.1.2	Symptoms of lung cancer	17

2.1.3	Pathogenesis of lung cancer	17
2.1.4	Prevention and treatment.....	18
2.2	Drug profile.....	21
2.2.1	Mechanism of action	22
2.2.2	Problems associated with marketed formulation	22
2.2.3	Resistance to Docetaxel.....	23
2.3	Gene delivery	25
2.3.1	RNAi mechanism.....	26
2.3.2	shRNA.....	27
2.3.3	In Vivo Delivery Vectors	28
2.4	POLYMER LIPID HYBRID NANOCARRIERS (PLHNC)	30
2.4.1	Types of lipid polymeric hybrid vesicles	31
2.4.2	Advantage of PLHNCs.....	32
2.4.3	Methods for preparation of PLHNCs.....	32
2.4.4	Recent literature on the Hybrid nanocarriers.....	34
2.5	Formulation Optimization.....	38
2.5.1	Experimental Designs	39
2.5.2	Design Augmentation.....	40
2.5.3	Response surface.....	40
2.5.4	Mathematical Models.....	42
2.6	Pulmonary delivery of PLHNCs	42
2.6.1	Dry Powder Inhalers:	42
2.6.2	Formulation of Dry Powder Inhalers:	43
2.6.3	Cascade Impactor-Inhaler Testing Equipment:	46
2.6.4	Parameters used to define lung deposition:	47
2.7	References	49

3 ANALYTICAL METHODS	54
3.1 INTRODUCTION.....	54
3.2 Analytical Method Validation.....	54
3.2.1 Linearity	54
3.2.2 Accuracy.....	54
3.2.3 Precision	54
3.2.4 Limit of Detection and Limit of Quantification:	55
3.3 Experimental work	55
3.3.1 Materials.....	55
3.3.2 Equipment.....	56
3.4 Estimation of Docetaxel by UV spectrophotometry.....	56
3.4.1 λ_{max} determination.....	56
3.4.2 Preparation of stock solution for calibration	56
3.4.3 Preparation of the Docetaxel calibration curve in acetonitrile	56
3.4.4 Docetaxel calibration plot in phosphate buffer pH 7.4	57
3.4.5 Docetaxel calibration plot in Phosphate buffer pH 6.6	57
3.5 Estimation of docetaxel by High performance liquid chromatography.....	59
3.5.1 Estimation of Docetaxel by RP-HPLC method.....	59
3.5.2 Calibration curve of Docetaxel by HPLC method.....	59
3.5.3 Calibration curve of Docetaxel in rat plasma by HPLC method	60
3.5.4 Calibration curve of Docetaxel in lung homogenate by HPLC method.....	61
3.5.5 Method validation	62
3.5.6 Estimation of total phospholipid content by Stewart method.....	62
3.5.7 Analytical Interference study.....	63
3.6 Analytical methods used for quantification of pDNA.....	63

3.6.1	UV Spectrophotometric Analysis of pDNA.....	63
3.6.2	Method for UV analysis of shRNA pDNA	64
3.7	Gel Electrophoresis of pDNA	64
3.7.1	Preparation of TAE buffer (Tris/Acetate/EDTA buffer, pH 8.4)	65
3.7.2	1.2% Agarose gel.....	65
3.7.3	EtBr stock solution (10 mg/mL)	65
3.7.4	Tank buffer:	66
3.7.5	Loading buffer:	66
3.7.6	Method of analysis.	66
3.8	Results and discussion	66
3.8.1	Estimation of Docetaxel by UV-VIS spectrophotometry	66
3.8.2	Estimation of Docetaxel using High Performance Liquid Chromatography (HPLC).....	77
3.8.3	Estimation of total phospholipid content by Stewart method.....	86
3.8.4	Analytical Interference study.....	88
3.8.5	Estimation of shRNA pDNA using UV spectrophotometry	89
3.8.6	Determination of detectable range of pDNA for Gel Retardation Assay	92
3.8.7	Relative Quantification	92
3.9	References	95
4	PREFORMULATION STUDIES	96
4.1	Introduction.....	96
4.2	List of Materials and Equipments.....	96
4.2.1	Materials	96
4.3	Characterization of Docetaxel.....	97
4.3.1	Organoleptic characterization.....	97

4.3.2	Melting Point Determination	97
4.3.3	Infrared Spectroscopy	97
4.4	DOCETAXEL-EXCIPIENTS COMPATIBILITY STUDIES	98
4.4.1	DSC	98
4.4.2	IR.....	98
4.5	shRNA pdna Working condition optimization.....	98
4.6	Results and Discussion	98
4.6.1	Organoleptic characterization of Docetaxel	98
4.6.2	Melting point determination	99
4.6.3	Authentication of drug by FTIR	99
4.6.4	Drug-excipients Compatibility Study	100
4.6.5	Optimization of working conditions for shRNA	102
4.7	References	105
5	FORMULATION & DEVELOPMENT OF DRUG AND GENE DUAL LOADED PLHNCS.....	106
5.1	introduction	106
5.2	Materials and instruments.....	106
5.2.1	Materials	106
5.2.2	Equipments	107
5.3	Formulation and development.....	108
5.3.1	Method of preparation.....	108
5.3.2	Preliminary screening study for formulation and process parameters	108
5.3.3	Selection of polymer	109
5.3.4	Effect of polymer concentration on encapsulation efficiency and particle size:.....	110

5.3.5	Effect of lipid to polymer ratio on drug encapsulation and particle size	110
5.3.6	Effect of drug input on encapsulation efficiency and particle size	113
5.3.7	Effect of lipid composition ratio on docetaxel encapsulation, particle size of PLHNCs and complexation efficiency of shRNA	113
5.3.8	Effect of process on encapsulation efficiency and particle size	114
5.4	Risk assessment	115
5.5	Quality by design	115
5.5.1	Plackett-Burman design for screening study (Primary design)	116
5.5.2	Box-behnken design for point prediction (Secondary design)	121
5.5.3	Desirability plot and overlay plot for optimization	141
5.5.4	Point prediction and confirmation	142
5.6	Characterization	142
5.6.1	Particle size and zeta potential determination	142
5.6.2	Determination of encapsulation efficiency of Docetaxel and complexation efficiency of shRNA	143
5.6.3	Phospholipid content by Stewart method	144
5.6.4	Scanning Electron Microscopy (SEM) Analysis	144
5.6.5	Transmission Electron Microscopy (TEM)	144
5.6.6	In-vitro drug release study and drug release kinetics	144
5.6.7	Estimation of residual solvent by Head space gas chromatography	147
5.6.8	Atomic force microscopy (AFM) analysis	148
5.7	Results and discussion	148
5.7.1	Particle size analysis of PLHNCs by dynamic light scattering (DLS)	148
5.7.2	Zeta potential of developed PLHNCs	149
5.7.3	Estimation of total phospholipid content	149

5.7.4	Scanning Electron Microscopy (SEM) Analysis	150
5.7.5	Transmission Electron Microscopy (TEM).....	150
5.7.6	In-vitro drug and pDNA release study and release kinetic	151
5.7.7	Estimation of residual solvent by HS-Gas Chromatography	154
5.7.8	Atomic Force Microscopy	155
5.8	References	156
6	DEVELOPMENT OF LYOPHILIZED DRY POWDER FORMULATION	157
6.1	Introduction.....	157
6.2	mATERIALS AND EQUIPMENTS	158
6.2.1	Materials	158
6.3	Preparation and characterization of lyophilized PLHNCs	159
6.3.1	Lyophilization procedure	159
6.3.2	Sf/Si ratio.....	159
6.3.3	Percentage drug retention.....	160
6.3.4	Moisture content analysis	160
6.3.5	Cryogenic and Freeze fracture transmission electron microscopy (cryo-TEM & FF-TEM).....	160
6.4	Preparation and characterization of dry powder formulation for inhalation	160
6.4.1	Development of dry powder formulation.....	160
6.4.2	In-vitro deposition studies	161
6.4.3	Compendial and non-compendial tests of developed PLHNCs dry powder.....	161
6.4.4	Scanning electron microscopy	162
6.4.5	Powder X-ray diffraction (PXRD).....	163
6.4.6	DSC	163
6.4.7	FT-IR.....	163

6.5	Integrity of shRNA pDNA AFTER DRY POWDER FORMULATION ..	163
6.6	Results and discussion	163
6.6.1	Optimization of lyophilization.....	163
6.6.2	Water content analysis	165
6.6.3	Cryo TEM and freeze-fracture TEM studies.....	165
6.6.4	Optimization of Dry powder formulation	166
6.6.5	Evaluation of dry powder for inhalation	167
6.6.6	Scanning electron microscopy	169
6.6.7	Powder X-ray diffraction (pXRD)	169
6.6.8	DSC	170
6.6.9	FT-IR.....	171
6.6.10	Integrity of shRNA pDNA after development of DPI	172
6.7	References	173
7	IN-VITRO CELL LINE STUDIES	174
7.1	Introduction.....	174
7.2	Materials and equipments.....	174
7.2.1	Materials	174
7.3	General methods and preparations	175
7.3.1	Preparation of complete media	175
7.3.2	Preparation of PBS (Phosphate Buffer Saline) pH 7.4	176
7.3.3	Preparation of FACS buffer.....	176
7.3.4	Sub-culturing of cells	176
7.4	In-vitro cell line studies	177
7.4.1	Development of Docetaxel resistant A-549 cell lines.....	177
7.4.2	In-vitro cytotoxicity	178
7.4.3	Cell migration assay	179

7.4.4	Cellular uptake studies	179
7.4.5	P-gp inhibition assay	180
7.4.6	Endocytic routes of sh-PLHNCs and FA-sh-PLHNCs	180
7.4.7	Apoptosis detection and cell cycle analysis	181
7.4.8	Quantitative RT-PCR	182
7.5	Results and Discussion	189
7.5.1	Functional characterization of developed Docetaxel resistant A549 cell line.	189
7.5.2	Cytotoxicity assay of various PLHNCs formulations	190
7.5.3	Characterization of cell migration (Scratch assay)	191
7.5.4	Qualitative uptake studies using confocal microscopy	193
7.5.5	Quantitative uptake studies using FACS.....	194
7.5.6	Effect of ABCB1 shRNA plasmid on P-gp activity	196
7.5.7	Determination of endocytic route	197
7.5.8	Cell apoptosis determination and cell cycle analysis.....	199
7.5.9	Inhibition of MDR1 mRNA levels by ABCB1 shRNA plasmid....	202
7.6	References:	204
8	IN-VIVO STUDIES.....	206
8.1	Introduction.....	206
8.2	Methods.....	206
8.2.1	Selection of animals	206
8.2.2	Housing and feeding conditions	206
8.2.3	Preparation of animals.....	206
8.3	Intratracheal Instillation.....	206
8.4	Acute toxicity study and maximum tolerated dose estimation	207
8.5	Pulmonary pharmacokinetics	208

8.6	Enzymatic activity estimation	209
8.7	In-vitro metabolism assay	209
8.8	Hemolytic study	210
8.8.1	Hemolytic study by UV method	210
8.8.2	Hemolytic study by Optical method	211
8.9	ResultS and discussion.....	211
8.9.1	Estimation of the maximum tolerated dose and LD ₅₀	211
8.9.2	Estimation of Docetaxel in lung homogenate (LH) and broncho- alveolar lavage (BAL fluid) after intra-tracheal and intravenous administration	213
8.9.3	Enzymatic activity estimation.....	215
8.9.4	Metabolism of Docetaxel by rat liver and lung microsomes.....	216
8.9.5	Hemolytic study by UV spectroscopy.....	216
8.9.6	Hemolytic study by optical method	217
8.10	References	218
9	STABILITY STUDIES	219
9.1	Introduction.....	219
9.2	Method for stability study	220
9.3	Serum stability study of shrna pDNA iN D-sh-PLHNCs	220
9.4	ResultS and discussion.....	221
9.4.1	Stability of PLHNC formulation as per ICH guidelines	221
9.4.2	Stability of shRNA pDNA in serum and simulated lung fluid.....	224
9.5	References	225
10	SUMMARY AND CONCLUSION.....	227
10.1	Summary.....	227
10.2	Conclusion	233